Clinical practice guidelines for the management of liver metastases from extrahepatic primary cancers 2021.
ablation therapy
disappearing liver metastases
hepatectomy
metastatic liver tumors
systemic therapy
Journal
Journal of hepato-biliary-pancreatic sciences
ISSN: 1868-6982
Titre abrégé: J Hepatobiliary Pancreat Sci
Pays: Japan
ID NLM: 101528587
Informations de publication
Date de publication:
Jan 2021
Jan 2021
Historique:
received:
30
09
2020
revised:
30
10
2020
accepted:
08
11
2020
pubmed:
18
11
2020
medline:
16
10
2021
entrez:
17
11
2020
Statut:
ppublish
Résumé
Hepatectomy is standard treatment for colorectal liver metastases; however, it is unclear whether liver metastases from other primary cancers should be resected or not. The Japanese Society of Hepato-Biliary-Pancreatic Surgery therefore created clinical practice guidelines for the management of metastatic liver tumors. Eight primary diseases were selected based on the number of hepatectomies performed for each malignancy per year. Clinical questions were structured in the population, intervention, comparison, and outcomes (PICO) format. Systematic reviews were performed, and the strength of recommendations and the level of quality of evidence for each clinical question were discussed and determined. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used to assess evidence and make recommendations. The eight primary sites were grouped into five categories based on suggested indications for hepatectomy and consensus of the guidelines committee. Fourteen clinical questions were devised, covering five topics: (1) diagnosis, (2) operative treatment, (3) ablation therapy, (4) the eight primary diseases, and (5) systemic therapies. The grade of recommendation was strong for one clinical question and weak for the other 13 clinical questions. The quality of the evidence was moderate for two questions, low for 10, and very low for two. A flowchart was made to summarize the outcomes of the guidelines for the indications of hepatectomy and systemic therapy. These guidelines were developed to provide useful information based on evidence in the published literature for the clinical management of liver metastases, and they could be helpful for conducting future clinical trials to provide higher-quality evidence.
Sections du résumé
BACKGROUND
BACKGROUND
Hepatectomy is standard treatment for colorectal liver metastases; however, it is unclear whether liver metastases from other primary cancers should be resected or not. The Japanese Society of Hepato-Biliary-Pancreatic Surgery therefore created clinical practice guidelines for the management of metastatic liver tumors.
METHODS
METHODS
Eight primary diseases were selected based on the number of hepatectomies performed for each malignancy per year. Clinical questions were structured in the population, intervention, comparison, and outcomes (PICO) format. Systematic reviews were performed, and the strength of recommendations and the level of quality of evidence for each clinical question were discussed and determined. The Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach was used to assess evidence and make recommendations.
RESULTS
RESULTS
The eight primary sites were grouped into five categories based on suggested indications for hepatectomy and consensus of the guidelines committee. Fourteen clinical questions were devised, covering five topics: (1) diagnosis, (2) operative treatment, (3) ablation therapy, (4) the eight primary diseases, and (5) systemic therapies. The grade of recommendation was strong for one clinical question and weak for the other 13 clinical questions. The quality of the evidence was moderate for two questions, low for 10, and very low for two. A flowchart was made to summarize the outcomes of the guidelines for the indications of hepatectomy and systemic therapy.
CONCLUSIONS
CONCLUSIONS
These guidelines were developed to provide useful information based on evidence in the published literature for the clinical management of liver metastases, and they could be helpful for conducting future clinical trials to provide higher-quality evidence.
Types de publication
Journal Article
Practice Guideline
Langues
eng
Sous-ensembles de citation
IM
Pagination
1-25Commentaires et corrections
Type : ErratumIn
Informations de copyright
© 2020 Japanese Society of Hepato-Biliary-Pancreatic Surgery.
Références
Van Cutsem E, Cervantes A, Adam R, Sobrero A, Van Krieken JH, Aderka D, et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol. 2016;27:1386-422.
Pavel M, O'Toole D, Costa F, Capdevila J, Gross D, Kianmanesh R, et al. ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site. Neuroendocrinology. 2016;103:172-85.
Sano K, Yamamoto M, Mimura T, Endo I, Nakamori S, Konishi M, et al. Japanese Society of Hepato-Biliary-Pancreatic Surgery. Outcomes of 1,639 hepatectomies for non-colorectal non-neuroendocrine liver metastases: a multicenter analysis. J Hepatobiliary Pancreat Sci. 2018;25:465-75.
Guyatt GH, Oxman AD, Vist GE, Kunz R, Falck-Ytter Y, Alonso-Coello P, et al. GRADE Working Group: GRADE: an emerging consensus on rating quality of evidence and strength of recommendations. BMJ. 2008;336:924-6.
Andrews J, Guyatt G, Oxman AD, Alderson P, Dahm P, Falck-Ytter Y, et al. GRADE guidelines: 14. Going from evidence to recommendations: the significance and presentation of recommendations. J Clin Epidemiol. 2013;66:719-25.
Andrews JC, Schunemann JC, Oxman AD, Pottie K, Meerpohl JJ, Coello PA, et al. GRADE guidelines: 15. Going from evidence to recommendation-determinants of a recommendation's direction and strength. J Clin Epidemiol. 2013;66:726-35.
Roh HJ, Kim DY, Joo WD, Yoo HJ, Kim JH, Kim YM, et al. Hepatic resection as part of secondary cytoreductive surgery for recurrent ovarian cancer involving the liver. Arch Gynecol Obstet. 2011;284:1223-9.
Lim MC, Kang S, Lee KS, Han SS, Park SJ, Seo SS, et al. The clinical significance of hepatic parenchymal metastasis in patients with primary epithelial ovarian cancer. Gynecol Oncol. 2009;112:28-34.
Rodriguez N, Miller A, Richard SD, Rungruang B, Hamilton CA, Bookman MA, et al. Upper abdominal procedures in advanced stage ovarian or primary peritoneal carcinoma patients with minimal or no gross residual disease: an analysis of Gynecologic Oncology Group (GOG) 182. Gynecol Oncol. 2013;130:487-92.
Frilling A, Clift AK. Therapeutic strategies for neuroendocrine liver metastases. Cancer. 2015;121:1172-86.
Pavel M, Baudin E, Couvelard A, Krenning E, Öberg K, Steinmüller T, et al. Barcelona Consensus Conference participants. ENETS Consensus Guidelines for the management of patients with liver and other distant metastases from neuroendocrine neoplasms of foregut, midgut, hindgut, and unknown primary. Neuroendocrinology. 2012;95:157-76.
Tsilimigras DI, Squires MH, Cloyd JM, Pawlik TM. Treatment strategies for neuroendocrine liver metastases: an update. Expert Opin Orphan Drugs. 2019;7:327-35.
Xia L, Zhang MM, Ji L, Li X, Wu XT. Resection combined with imatinib therapy for liver metastases of gastrointestinal stromal tumors. Surg Today. 2010;40:936-42.
Shi YN, Li Y, Wang LP, Wang ZH, Liang XB, Liang H, et al. Gastrointestinal stromal tumor (GIST) with liver metastases: An 18-year experience from the GIST cooperation group in north china. Medicine (Baltimore). 2017;96:e8240.
Kinoshita T, Kinoshita T, Saiura A, Esaki M, Sakamoto H, Yamanaka T. Multicentre analysis of long-term outcome after surgical resection for gastric cancer liver metastases. Br J Surg. 2015;102:102-7.
Oki E, Tokunaga S, Emi Y, Kusumoto T, Yamamoto M, Fukuzawa K, et al. Surgical treatment of liver metastasis of gastric cancer: a retrospective multicenter cohort study (KSCC1302). Gastric Cancer. 2016;19:968-76.
Kurosaki I, Minagawa M, Kitami C, Takano K, Hatakeyama K. Hepatic resection for liver metastases from carcinomas of the distal bile duct and of the papilla of Vater. Langenbecks Arch Surg. 2011;396:607-13.
Motoyama H, Kobayashi A, Yokoyama T, Shimizu A, Kitagawa N, Notake T, et al. Survival benefits of surgical resection in patients with recurrent biliary tract carcinoma. World J Surg. 2017;41:2817-29.
Portier G, Elias D, Bouche O, Rougier P, Bosset JF, Saric J, et al. Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. J Clin Oncol. 2006;24:4976-82.
Hasegawa K, Saiura A, Takayama T, Miyagawa S, Yamamoto J, Ijichi M, et al. Adjuvant oral uracil-tegafur with leucovorin for colorectal cancer liver metastases: A randomized controlled trial. PLoS One. 2016;11:e0162400.
Mitry E, Fields AL, Bleiberg H, Labianca R, Portier G, Tu D, et al. Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: A pooled analysis of two randomized trials. J Clin Oncol. 2008;26:4906-11.
Sakamoto Y, Ohyama S, Yamamoto J, Yamada K, Seki M, Ohta K, et al. Surgical resection of liver metastases of gastric cancer: an analysis of a 17-year experience with 22 patients. Surgery. 2003;133:507-11.
Koga R, Yamamoto J, Ohyama S, Saiura A, Seki M, Seto Y, et al. Liver resection for metastatic gastric cancer: experience with 42 patients including eight long-term survivors. Jpn J Clin Oncol. 2007;37:836-42.
Makino H, Kunisaki C, Izumisawa Y, Tokuhisa M, Oshima T, Nagano Y, et al. Indication for hepatic resection in the treatment of liver metastasis from gastric cancer. Anticancer Res. 2010;30:2367-76.
Komeda K, Hayashi M, Kubo S, Nagano H, Nakai T, Kaibori M, et al. High survival in patients operated for small isolated liver metastases from gastric cancer: a multi-institutional study. World J Surg. 2014;38:2692-7.
Ikari N, Taniguchi K, Serizawa A, Yamada T, Yamamoto M, Furukawa T, et al. A primary tumor of mixed histological type is a novel poor prognostic factor for patients undergoing resection of liver metastasis from gastric cancer. J Hepatobiliary Pancreat Sci. 2017;24:281-8.
Adam R, Delvart V, Valeanu PG, Castaing D, Azoulay D, Giacchetti S, et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy: a model to predict long-term survival. Ann Surg. 2004;240:644-57.
Nuzzo G, Giuliante F, Ardito F, Vellone M, Ardito F, Sarno G, et al. Liver resection for primarily unresectable colorectal metastases downsized by chemotherapy. J Gastrointest Surg. 2007;11:318-24.
Kataoka K, Kanazawa A, Iwamoto S, Kato T, Nakajima A, Arimoto A. Does, "conversion chemotherapy" really improve survival in metastatic colorectal cancer patients with liver-limited disease? World J Surg. 2014;38:936-46.
Berger-Kulemann V, Schima W, Baroud S, Koelblinger C, Kaczirek K, Gruenberger T, et al. Gadoxetic acid-enhanced 3.0 T MR imaging versus multidetector-row CT in the detection of colorectal metastases in fatty liver using intraoperative ultrasound and histopathology as a standard of reference. Eur J Surg Oncol. 2012;38:670-6.
Koh DM, Collins DJ, Wallace T, Chau I, Riddell AM. Combining diffusion-weighted MRI with Gd-EOB-DTPA-enhanced MRI improves the detection of colorectal liver metastases. Br J Radiol. 2012;85:980-9.
Arita J, Ono Y, Takahashi M, Inoue Y, Takahashi Y, Matsueda K, et al. Routine preoperative liver-specific magnetic resonance imaging does not exclude the necessity of contrast-enhanced intraoperative ultrasound in hepatic resection for colorectal liver metastasis. Ann Surg. 2015;262:1086-91.
Cho JY, Lee YJ, Han HS, Yoon YS, Kim J, Choi Y, et al. Role of gadoxetic acid-enhanced magnetic resonance imaging in the preoperative evaluation of small hepatic lesions in patients with colorectal cancer. World J Surg. 2015;39:1161-6.
Chung WS, Kim MJ, Chung YE, Kim YE, Park MS, Choi JY, et al. Comparison of gadoxetic acid-enhanced dynamic imaging and diffusion-weighted imaging for the preoperative evaluation of colorectal liver metastases. J Magn Reson Imaging. 2011;34:345-53.
Colagrande S, Castellani A, Nardi C, Lorini C, Calistri L, Filippone A. The role of diffusion-weighted imaging in the detection of hepatic metastases from colorectal cancer: A comparison with unenhanced and Gd-EOB-DTPA enhanced MRI. Eur J Radiol. 2016;85:1027-34.
Donati OF, Hany TF, Reiner CS, von Schulthess GK, Marincek B, Seifert B, et al. Value of retrospective fusion of PET and MR images in detection of hepatic metastases: comparison with 18F-FDG PET/CT and Gd-EOB-DTPA-enhanced MRI. J Nucl Med. 2010;51:692-9.
Macera A, Lario C, Petracchini M, Gallo T, Regge D, Floriani I, et al. Staging of colorectal liver metastases after preoperative chemotherapy. Diffusion-weighted imaging in combination with Gd-EOB-DTPA MRI sequences increases sensitivity and diagnostic accuracy. Eur Radiol. 2013;23:739-47.
Rojas Llimpe FL, Di Fabio F, Ercolani G, Giampalma E, Cappelli A, Serra C, et al. Imaging in resectable colorectal liver metastasis patients with or without preoperative chemotherapy: results of the PROMETEO-01 study. Br J Cancer. 2014;111:667-73.
Schulz A, Viktil E, Godt JC, Johansen CK, Dormagen JB, Holtedahl JE, et al. Diagnostic performance of CT, MRI and PET/CT in patients with suspected colorectal liver metastases: the superiority of MRI. Acta Radiol. 2016;57:1040-8.
Sofue K, Tsurusaki M, Tokue H, Arai Y, Sugimura K. Gd-EOB-DTPA-enhanced 3.0 T MR imaging: quantitative and qualitative comparison of hepatocyte-phase images obtained 10 min and 20 min after injection for the detection of liver metastases from colorectal carcinoma. Eur Radiol. 2011;21:2336-43.
Cantisani V, Ricci P, Erturk M, Pagliara E, Drudi F, Calliada F, et al. Detection of hepatic metastases from colorectal cancer: prospective evaluation of gray scale US versus SonoVue (R) low mechanical index real time-enhanced US as compared with multidetector-CT or Gd-BOPTA-MRI. Ultraschall Med. 2010;31:500-5.
Fioole B, de Haas RJ, Wicherts DA, Elias SG, Scheffers JM, van Hillegersberg R, et al. Additional value of contrast enhanced intraoperative ultrasound for colorectal liver metastases. Eur J Radiol. 2008;67:169-76.
Garcia Vicente AM, Dominguez Ferreras E, Sanchez Perez V, Poblete Garcia VM, Villa Guzman JC, Jimenez Aragon F, et al. Response assessment of colorectal liver metastases with contrast enhanced CT/18F-FDG PET. Eur J Radiol. 2013;82:e255-e261.
Lubezky N, Metser U, Geva R, Nakache R, Shmueli E, Klausner JM, et al. The role and limitations of 18-fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) scan and computerized tomography (CT) in restaging patients with hepatic colorectal metastases following neoadjuvant chemotherapy: comparison with operative and pathological findings. J Gastrointest Surg. 2007;11:472-8.
Nanashima A, Takeshita H, Sawai T, Sumida Y, Abo T, Tanaka K, et al. Preoperative assessment of liver metastasis originating from colorectal carcinoma: is super paramagnetic iron oxide particles-magnetic resonance imaging (SPIO-MRI) useful for screening? Hepatogastroenterology. 2008;55:1750-3.
Ramos E, Valls C, Martinez L, Llado L, Torras J, Ruiz S, et al. Preoperative staging of patients with liver metastases of colorectal carcinoma. Does PET/CT really add something to multidetector CT? Ann Surg Oncol. 2011;18:2654-61.
Chen L, Zhang J, Zhang L, Bao J, Liu C, Xia Y, et al. Meta-analysis of gadoxetic acid disodium (Gd-EOB-DTPA)-enhanced magnetic resonance imaging for the detection of liver metastases. PLoS One. 2012;7:e48681.
Choi SH, Kim SY, Park SH, Kim KW, Lee JY, Lee SS, et al. Diagnostic performance of CT, gadoxetate disodium-enhanced MRI, and PET/CT for the diagnosis of colorectal liver metastasis: Systematic review and meta-analysis. J Magn Reson Imaging. 2018;47:1237-50.
Zech CJ, Korpraphong P, Huppertz A, Denecke T, Kim MJ, Tanomkiat W, et al. Randomized multicentre trial of gadoxetic acid-enhanced MRI versus conventional MRI or CT in the staging of colorectal cancer liver metastases. Br J Surg. 2014;101:613-21.
Achiam MP, Logager VB, Skjoldbye B, Moller JM, Lorenzen T, Rasmussen VL, et al. Preoperative CT versus diffusion weighted magnetic resonance imaging of the liver in patients with rectal cancer; a prospective randomized trial. PeerJ. 2016;4:e1532.
Zech CJ, Justo N, Lang A, Ba-Ssalamah A, Kim MJ, Rinde H, et al. Cost evaluation of gadoxetic acid-enhanced magnetic resonance imaging in the diagnosis of colorectal-cancer metastasis in the liver: Results from the VALUE Trial. Eur Radiol. 2016;26:4121-30.
Saing S, Haywood P, Duncan JK, Ma N, Cameron AL, Goodall S. Cost-effective imaging for resectability of liver lesions in colorectal cancer: an economic decision model. ANZ J Surg. 2018;88(6):E507-E511.
Tani K, Shindoh J, Akamatsu N, Arita J, Kaneko J, Sakamoto Y, et al. Management of disappearing lesions after chemotherapy for colorectal liver metastases: Relation between detectability and residual tumors. J Surg Oncol. 2018;117:191-7.
Park MJ, Hong N, Han K, Kim MJ, Lee YJ, Park YS, et al. Use of Imaging to predict complete response of colorectal liver metastases after chemotherapy: MR imaging versus CT imaging. Radiology. 2017;284:423-31.
Kim SS, Song KD, Kim YK, Kim HC, Huh JW, Park YS, et al. Disappearing or residual tiny (≤5 mm) colorectal liver metastases after chemotherapy on gadoxetic acid-enhanced liver MRI and diffusion-weighted imaging: Is local treatment required? Eur Radiol. 2017;27:3088-96.
Donadon M, Cescon M, Cucchetti A, Cimino M, Costa G, Pesi B, et al. Parenchymal-sparing surgery for the surgical treatment of multiple colorectal liver metastases is a safer approach than major hepatectomy not impairing patients' prognosis: A bi-Institutional propensity score-matched analysis. Dig Surg. 2018;35:342-9.
Memeo R, de Blasi V, Adam R, Goéré D, Azoulay D, Ayav A, et al. French Colorectal Liver Metastases Working Group, Association Française de Chirurgie (AFC). Parenchymal-sparing hepatectomies (PSH) for bilobar colorectal liver metastases are associated with a lower morbidity and similar oncological results: a propensity score matching analysis. HPB (Oxford). 2016;18:781-90.
Lordan JT, Roberts JK, Hodson J, Isaac J, Muiesan P, Mirza DF, et al. Case-controlled study comparing peri-operative and cancer-related outcomes after major hepatectomy and parenchymal sparing hepatectomy for metastatic colorectal cancer. HPB (Oxford). 2017;19:688-94.
Mise Y, Aloia TA, Brudvik KW, Schwarz L, Vauthey JN, Conrad C. Parenchymal-sparing hepatectomy in colorectal liver metastasis improves salvageability and survival. Ann Surg. 2016;263:146-52.
Hosokawa I, Allard MA, Mirza DF, Kaiser G, Barroso E, Lapointe R, et al. Outcomes of parenchyma-preserving hepatectomy and right hepatectomy for solitary small colorectal liver metastasis: A LiverMetSurvey study. Surgery. 2017;162:223-32.
Matsumura M, Mise Y, Saiura A, Inoue Y, Ishizawa T, Ichida H, et al. Parenchymal-sparing hepatectomy does not increase intrahepatic recurrence in patients with advanced colorectal liver metastases. Ann Surg Oncol. 2016;23:3718-26.
Matsuki R, Mise Y, Saiura A, Inoue Y, Ishizawa T, Takahashi Y. Parenchymal-sparing hepatectomy for deep-placed colorectal liver metastases. Surgery. 2016;160:1256-63.
Fretland AA, Dagenborg VJ, Bjornelv GMW, Kazaryan AM, Kristiansen R, Fagerland MW, et al. Laparoscopic versus open resection for colorectal liver metastases: The OSLO-COMET Randomized Controlled Trial. Ann Surg. 2018;267:199-207.
Robles-Campos R, Lopez-Lopez V, Brusadin R, Lopez-Conesa A, Gil-Vazquez PJ, Navarro-Barrios A, et al. Open versus minimally invasive liver surgery for colorectal liver metastases (LapOpHuva): a prospective randomized controlled trial. Surg Endosc. 2019;33:3926-36.
Fretland AA, Dagenborg VJ, Waaler Bjornelv GM, Aghayan DL, Kazaryan AM, Barkhatov L, et al. Quality of life from a randomized trial of laparoscopic or open liver resection for colorectal liver metastases. Br J Surg. 2019;106:1372-80.
Beppu T, Wakabayashi G, Hasegawa K, Gotohda N, Mizuguchi T, Takahashi Y, et al. Long-term and perioperative outcomes of laparoscopic versus open liver resection for colorectal liver metastases with propensity score matching: a multi-institutional Japanese study. J Hepatobiliary Pancreat Sci. 2015;22:711-20.
Cannon RM, Scoggins CR, Callender GG, McMasters KM, Martin RC. Laparoscopic versus open resection of hepatic colorectal metastases. Surgery. 2012;152:567-73.
Cipriani F, Rawashdeh M, Stanton L, Armstrong T, Takhar A, Pearce NW, et al. Propensity score-based analysis of outcomes of laparoscopic versus open liver resection for colorectal metastases. Br J Surg. 2016;103:1504-12.
Lewin JW, O'Rourke NA, Chiow AKH, Bryant R, Martin I, Nathanson LK, et al. Long-term survival in laparoscopic vs open resection for colorectal liver metastases: inverse probability of treatment weighting using propensity scores. HPB (Oxford). 2016;18:183-91.
Lin Q, Ye Q, Zhu D, Wei Y, Ren L, Zheng P, et al. Comparison of minimally invasive and open colorectal resections for patients undergoing simultaneous R0 resection for liver metastases: a propensity score analysis. Int J Colorectal Dis. 2015;30:385-95.
Martinez-Cecilia D, Cipriani F, Vishal S, Ratti F, Tranchart H, Barkhatov L, et al. Laparoscopic versus open liver resection for colorectal metastases in elderly and octogenarian patients: A multicenter propensity score based analysis of short- and long-term outcomes. Ann Surg. 2017;265:1192-200.
Tranchart H, Fuks D, Vigano L, Ferretti S, Paye F, Wakabayashi G, et al. Laparoscopic simultaneous resection of colorectal primary tumor and liver metastases: a propensity score matching analysis. Surg Endosc. 2016;30:1853-62.
Allard MA, Cunha AS, Gayet B, Adam R, Goere D, Bachellier P, et al. Early and long-term oncological outcomes after laparoscopic resection for colorectal liver metastases: A propensity score-based analysis. Ann Surg. 2015;262:794-802.
Ratti F, Fiorentini G, Cipriani F, Catena M, Paganelli M, Aldrighetti L. Laparoscopic vs open surgery for colorectal liver metastases. JAMA Surg. 2018;153:1028-35.
Untereiner X, Cagniet A, Memeo R, Tzedakis S, Piardi T, Severac F, et al. Laparoscopic hepatectomy versus open hepatectomy for colorectal cancer liver metastases: comparative study with propensity score matching. Hepatobiliary Surg Nutr. 2016;5:290-9.
Zeng Y, Tian M. Laparoscopic versus open hepatectomy for elderly patients with liver metastases from colorectal cancer. J BUON. 2016;21:1146-52.
Syn NL, Kabir T, Koh YX, Tan HL, Wang LZ, et al. Survival advantage of laparoscopic versus open resection for colorectal liver metastases: A meta-analysis of individual patient data from randomized trials and propensity-score matched studies. Ann Surg. 2020;272:253-65.
Li J, Xi H, Cui J, Zhang K, Gao Y, Liang W, et al. Minimally invasive surgery as a treatment option for gastric cancer with liver metastasis: a comparison with open surgery. Surg Endosc. 2018;32:1422-33.
Agcaoglu O, Aliyev S, Karabulut K, El-Gazzaz G, Aucejo F, Pelley R, et al. Complementary use of resection and radiofrequency ablation for the treatment of colorectal liver metastases: an analysis of 395 patients. World J Surg. 2013;37:1333-9.
Gleisner AL, Choti MA, Assumpcao L, Nathan H, Schulick RD, Pawlik TM. Colorectal liver metastases: recurrence and survival following hepatic resection, radiofrequency ablation, and combined resection-radiofrequency ablation. Arch Surg. 2008;143:1204-12.
Berber E, Tsinberg M, Tellioglu G, Simpfendorfer CH, Siperstein AE. Resection versus laparoscopic radiofrequency thermal ablation of solitary colorectal liver metastasis. J Gastrointest Surg. 2008;12:1967-72.
Hof J, Wertenbroek MW, Peeters PM, Widder J, Sieders E, de Jong KP. Outcomes after resection and/or radiofrequency ablation for recurrence after treatment of colorectal liver metastases. Br J Surg. 2016;103:1055-62.
Kim KH, Yoon YS, Yu CS, Kim TW, Kim HJ, Kim PN, et al. Comparative analysis of radiofrequency ablation and surgical resection for colorectal liver metastases. J Korean Surg Soc. 2011;81:25-34.
Ko S, Jo H, Yun S, Park E, Kim S, Seo H, et al. Comparative analysis of radiofrequency ablation and resection for resectable colorectal liver metastases. World J Gastroenterol. 2014;20:525-31.
Lee KH, Kim HO, Yoo CH, Son BH, Park YL, Cho YK, et al. Comparison of radiofrequency ablation and resection for hepatic metastasis from colorectal cancer. Korean J Gastroenterol. 2012;59:218-23.
Lee H, Heo JS, Cho YB, Yun SH, Kim HC, Lee WY, et al. Hepatectomy vs radiofrequency ablation for colorectal liver metastasis: a propensity score analysis. World J Gastroenterol. 2015;21:3300-7.
Mckay A, Fradette K, Lipschitz J. Long-term outcomes following hepatic resection and radiofrequency ablation of colorectal liver metastases. HPB Surg. 2009;346863: https://doi.org/10.1155/2009/346863.
Park IJ, Kim HC, Yu CS, Kim PN, Won HJ, Kim JC. Radiofrequency ablation for metachronous liver metastasis from colorectal cancer after curative surgery. Ann Surg Oncol. 2008;15:227-32.
Reuter NP, Woodall CE, Scoggins CR, McMasters KM, Martin RCG. Radiofrequency ablation vs. resection for hepatic colorectal metastasis: therapeutically equivalent? J Gastrointest Surg. 2009;13:486-91.
Abdalla EK, Vauthey JN, Ellis LM, Ellis V, Pollock R, Broglio KR, et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg. 2004;239:818-25.
Nishiwada S, Ko S, Mukogawa T, Ishikawa H, Matsusaka M, Nakatani T, et al. Comparison between percutaneous radiofrequency ablation and surgical hepatectomy focusing on local disease control rate for colorectal liver metastases. Hepatogastroenterology. 2014;61:436-41.
Shimizu T, Tanaka K, Makino H, Matsuo K, Ueda M, Nagano Y, et al. Microwave ablation for multiple bilobar liver tumors from colorectal cancer. Gan To Kagaku Ryoho. 2005;32:1646-8.
Tanaka K, Shimada H, Nagano Y, Endo I, Sekido H, Togo S, et al. Outcome after hepatic resection versus combined resection and microwave ablation for multiple bilobar colorectal metastases to the liver. Surgery. 2006;139:263-73.
Leblanc F, Fonck M, Brunet R, Becouarn Y, Mathoulin-Pélissier S, Evrard S, et al. Comparison of hepatic recurrences after resection or intraoperative radiofrequency ablation indicated by size and topographical characteristics of the metastases. Eur J Surg Oncol. 2008;34:185-90.
Reissfelder C, Rahbari NN, Bejarano LU, Schmidt T, Kortes N, Kauczor HU, et al. Comparison of various surgical approaches for extensive bilateral colorectal liver metastases. Langenbecks Arch Surg. 2014;399:481-91.
Boame N, Gresham G, Jonker D, Martel G, Balaa F, Asmis T. Use of chemotherapy and radiofrequency ablation to treat colorectal cancer metastases: a retrospective review of The Ottawa Hospital Cancer Centre over 7 years. Curr Oncol. 2014;21:e557-e563.
Imai K, Allard MA, Castro Benitez C, Vibert E, Sa Cunha A, Cherqui D, et al. Long-term outcomes of radiofrequency ablation combined with hepatectomy compared with hepatectomy alone for colorectal liver metastases. Br J Surg. 2017;104:570-9.
Mima K, Beppu T, Chikamoto A, Miyamoto Y, Nakagawa S, Kuroki H, et al. Hepatic resection combined with radiofrequency ablation for initially unresectable colorectal liver metastases after effective chemotherapy is a safe procedure with a low incidence of local recurrence. Int J Clin Oncol. 2013;18:847-55.
Ruers T, Punt C, Van Coevorden F, Pierie JP, Borel-Rinkes I, Ledermann JA, et al. Radiofrequency ablation combined with systemic treatment versus systemic treatment alone in patients with non-resectable colorectal liver metastases: a randomized EORTC Intergroup phase II study (EORTC 40004). Ann Oncol. 2012;23:2619-26.
Ruers T, Van Coevorden F, Punt CJ, Pierie JE, Borel-Rinkes I, Ledermann JA, et al. Local treatment of unresectable colorectal liver metastases: results of a randomized phase II trial. J Natl Cancer Inst. 2017;109(9):djx015.
Li J, Zhang K, Gao Y, Xi H, Cui J, Liang W, et al. Evaluation of hepatectomy and palliative local treatments for gastric cancer patients with liver metastases: a propensity score matching analysis. Oncotarget. 2017;8:61861-75.
Xiao YB, Zhang B, Wu YL. Radiofrequency ablation versus hepatic resection for breast cancer liver metastasis: a systematic review and meta-analysis. J Zhejiang Univ Sci B. 2018;19:829-43.
Robbert SP, Alette HR, Laurien GPHV, Aukje AJM, Hester JS, Karin N, et al. Colorectal liver metastases: surgery versus thermal ablation (COLLISION) - a phase III single-blind prospective randomized controlled trial. BMC Cancer. 2018;15(18):821.
Takahashi H, Kahramangil B, Kose E, Berber E. A comparison of microwave thermosphere versus radiofrequency thermal ablation in the treatment of colorectal liver metastases. HPB (Oxford). 2018;20:1157-62.
Fukami Y, Kaneoka Y, Maeda A, Takayama Y, Takahashi T, Uji M, et al. Adjuvant hepatic artery infusion chemotherapy after hemihepatectomy for gastric cancer liver metastases. Int J Surg. 2017;46:79-84.
Qiu JL, Deng MG, Li W, Zou RH, Li BK, Zheng Y, et al. Hepatic resection for synchronous hepatic metastasis from gastric cancer. Eur J Surg Oncol. 2013;39:694-700.
Tiberio GA, Roviello F, Donini A, de Manzoni G. Hepatic metastases from gastric cancer: A surgical perspective. World J Gastroenterol. 2015;21:11489-92.
Shirasu H, Tsushima T, Kawahira M, Kawai S, Kawakami T, Kito Y, et al. Role of hepatectomy in gastric cancer with multiple liver-limited metastases. Gastric Cancer. 2018;21:338-44.
Tiberio GA, Ministrini S, Gardini A, Marrelli D, Marchet A, Cipollari C, et al. Factors influencing survival after hepatectomy for metastases from gastric cancer. Eur J Surg Oncol. 2016;42:1229-35.
Grimes N, Devlin J, Dunne DF, Poston G, Fenwick S, Malik H. The role of hepatectomy in the management of metastatic gastric adenocarcinoma: a systematic review. Surg Oncol. 2014;23:177-85.
Kerkar SP, Kemp CD, Avital I. Liver resections in metastatic gastric cancer. HPB. (Oxford). 2010;12:589-96.
Tiberio GA, Baiocchi GL, Morgagni P, Marrelli D, Marchet A, Cipollari C, et al. Gastric cancer and synchronous hepatic metastases: is it possible to recognize candidates to R0 resection? Ann Surg Oncol. 2015;22:589-96.
Takemura N, Saiura A, Koga R, Arita J, Yoshioka R, Ono Y, et al. Long-term outcomes after surgical resection for gastric cancer liver metastasis: an analysis of 64 macroscopically complete resections. Langenbecks Arch Surg. 2012;397:951-7.
Kodera Y, Fujitani K, Fukushima N, Ito S, Muro K, Ohashi N, et al. Surgical resection of hepatic metastasis from gastric cancer: a review and new recommendation in the Japanese gastric cancer treatment guidelines. Gastric Cancer. 2014;17:206-12.
Wang YN, Shen KT, Ling JQ, Gao XD, Hou YY, Wang XF, et al. Prognostic analysis of combined curative resection of the stomach and liver lesions in 30 gastric cancer patients with synchronous liver metastases. BMC Surg. 2012;12:20.
Schildberg CW, Croner R, Merkel S, Schellerer V, Muller V, Yedibela S, et al. Outcome of operative therapy of hepatic metastatic stomach carcinoma: a retrospective analysis. World J Surg. 2012;36:872-8.
Garancini M, Uggeri F, Degrate L, Nespoli L, Gianotti L, Nespoli A, et al. Surgical treatment of liver metastases of gastric cancer: is local treatment in a systemic disease worthwhile? HPB (Oxford). 2012;14:209-15.
Miki Y, Fujitani K, Hirao M, Kurokawa Y, Mano M, Tsujie M, et al. Significance of surgical treatment of liver metastases from gastric cancer. Anticancer Res. 2012;32:665-70.
Tsujimoto H, Ichikura T, Ono S, Sugasawa H, Hiraki S, Sakamoto N, et al. Outcomes for patients following hepatic resection of metastatic tumors from gastric cancer. Hepatol Int. 2010;4:406-13.
Cheon SH, Rha SY, Jeung HC, Im CK, Kim SH, Kim HR, et al. Survival benefit of combined curative resection of the stomach (D2 resection) and liver in gastric cancer patients with liver metastases. Ann Oncol. 2008;19:1146-53.
Thelen A, Jonas S, Benckert C, Lopez-Hanninen E, Neumann U, Rudolph B, et al. Liver resection for metastatic gastric cancer. Eur J Surg Oncol. 2008;34:1328-34.
Morise Z, Sugioka A, Hoshimoto S, Kato T, Ikeda M, Uyama I, et al. The role of hepatectomy for patients with liver metastases of gastric cancer. Hepatogastroenterology. 2008;55:1238-41.
Shinohara T, Maeda Y, Hamada T, Futakawa N. Survival benefit of surgical treatment for liver metastases from gastric cancer. J Gastrointest Surg. 2015;19:1043-51.
Tatsubayashi T, Tanizawa Y, Miki Y, Tokunaga M, Bando E, Kawamura T, et al. Treatment outcomes of hepatectomy for liver metastases of gastric cancer diagnosed using contrast-enhanced magnetic resonance imaging. Gastric Cancer. 2017;20:387-93.
Guner A, Son T, Cho I, Kwon IG, An JY, Kim HI, et al. Liver-directed treatments for liver metastasis from gastric adenocarcinoma: comparison between liver resection and radiofrequency ablation. Gastric Cancer. 2016;19:951-60.
Seesing MF, Tielen R, van Hillegersberg R, van Coevorden F, de Jong KP, Nagtegaal ID, et al. Dutch Liver Surgery Working Group. Resection of liver metastases in patients with gastrointestinal stromal tumors in the imatinib era: A nationwide retrospective study. Eur J Surg Oncol. 2016;42:1407-13.
Brudvik KW, Patel SH, Roland CL, Conrad C, Torres KE, Hunt KK, et al. Survival after resection of gastrointestinal stromal tumor and sarcoma liver metastases in 146 patients. J Gastrointest Surg. 2015;19:1476-83.
Cheung TT, Chok KS, Chan AC, Yau TC, Chan SC, Poon RT, et al. Analysis of long-term survival after hepatectomy for isolated liver metastasis of gastrointestinal stromal tumour. ANZ J Surg. 2014;84:827-31.
Gomez D, Al-Mukthar A, Menon KV, Toogood GJ, Lodge JP, Prasad KR. Aggressive surgical resection for the management of hepatic metastases from gastrointestinal stromal tumours: A single centre experience. HPB (Oxford). 2007;9:64-70.
Machairas N, Prodromidou A, Molmenti E, Kostakis ID, Sotiropoulos GC. Management of liver metastases from gastrointestinal stromal tumors: Where do we stand? J Gastrointest Oncol. 2017;8:1100-8.
Vassos N, Agaimy A, Hohenberger W, Croner RS. Management of liver metastases of gastrointestinal stromal tumors (GIST). Ann Hepatol. 2015;14:531-9.
Shima Y, Horimi T, Ishikawa T, Ichikawa J, Okabayashi T, Nishioka Y, et al. Aggressive surgery for liver metastases from gastrointestinal stromal tumors. J Hepatobiliary Pancreat Surg. 2003;10:77-80.
Turley RS, Peng PD, Reddy SK, Barbas AS, Geller DA, Marsh JW, et al. Hepatic resection for metastatic gastrointestinal stromal tumors in the tyrosine kinase inhibitor era. Cancer. 2012;118:3571-8.
Cananzi FC, Belgaumkar A, Lorenzi B, Mudan S. Liver surgery in the multidisciplinary management of gastrointestinal stromal tumour. ANZ J Surg. 2014;84:937-42.
Du CY, Zhou Y, Song C, Wang YP, Jie ZG, He YL, et al. Is there a role of surgery in patients with recurrent or metastatic gastrointestinal stromal tumours responding to imatinib: A prospective randomised trial in China? Eur J Cancer. 2014;50:1772-8.
Bauer S, Rutkowski P, Hohenberger P, Miceli R, Fumagalli E, Siedlecki JA, et al. Long-term follow-up of patients with GIST undergoing metastasectomy in the era of imatinib - analysis of prognostic factors (EORTC-STBSG collaborative study). Eur J Surg Oncol. 2014;40:412-9.
Antonescu CR, Besmer P, Guo T, Arkun K, Hom G, Koryotowski B, et al. Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation. Clin Cancer Res. 2005;11:4182-90.
Joensuu H, Eriksson M, Sundby Hall K, Hartmann JT, Pink D, Schutte J, et al. One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: A randomized trial. JAMA. 2012;307:1265-72.
Raut CP, Wang Q, Manola J, Morgan JA, George S, Wagner AJ, et al. Cytoreductive surgery in patients with metastatic gastrointestinal stromal tumor treated with sunitinib malate. Ann Surg Oncol. 2010;17:407-15.
Takahashi Y, Ebata T, Yokoyama Y, Igami T, Sugawara G, Mizuno T, et al. Surgery for recurrent biliary tract cancer: A single-center experience with 74 consecutive resections. Ann Surg. 2015;262:121-9.
Bristow RE, Montz FJ, Lagasse LD, Leuchter RS, Karlan BY. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer. Gynecol Oncol. 1999;72:278-87.
Bristow RE, Tomacruz RS, Armstrong DK, Trimble EL, Montz FJ. Survival effect of maximal cytoreductive surgery for advanced ovarian carcinoma during the platinum era: a meta-analysis. J Clin Oncol. 2002;20:1248-59.
Tian WJ, Jiang R, Cheng X, Tang J, Xing Y, Zang RY. Surgery in recurrent epithelial ovarian cancer: benefits on Survival for patients with residual disease of 0.1-1 cm after secondary cytoreduction. J Surg Oncol. 2010;101:244-50.
Crawford SC, Vasey PA, Paul J, Hay A, Davis JA, Kaye SB. Does aggressive surgery only benefit patients with less advanced ovarian cancer? Results from an international comparison within the SCOTROC-1 Trial. J Clin Oncol. 2005;23:8802-11.
Abood G, Bowen M, Potkul R, Aranha G, Shoup M. Hepatic resection for recurrent metastatic ovarian cancer. Am J Surg. 2008;195:370-3.
Niu GC, Shen CM, Cui W, Li Q. Hepatic resection is safe for metachronous hepatic metastases from ovarian cancer. Cancer Biol Med. 2012;9:182-7.
Kolev V, Pereira EB, Schwartz M, Sarpel U, Roayaie S, Labow D, et al. The role of liver resection at the time of secondary cytoreduction in patients with recurrent ovarian cancer. Int J Gynecol Cancer. 2014;24:70-4.
Merideth MA, Cliby WA, Keeney GL, Lesnick TG, Nagorney DM, Podratz KC. Hepatic resection for metachronous metastases from ovarian carcinoma. Gynecol Oncol. 2003;89:16-21.
Neumann UP, Fotopoulou C, Schmeding M, Thelen A, Papanikolaou G, Braicu EI, et al. Clinical outcome of patients with advanced ovarian cancer after resection of liver metastases. Anticancer Res. 2012;32:4517-21.
Bacalbasa N, Dima S, Brasoveanu V, David L, Balescu I, Purnichescu-Purtan R, et al. Liver resection for ovarian cancer liver metastases as part of cytoreductive surgery is safe and may bring survival benefit. World J Surg Oncol. 2015;13:235.
Gasparri ML, Grandi G, Bolla D, Gloor B, Imboden S, Panici PB, et al. Hepatic resection during cytoreductive surgery for primary or recurrent epithelial ovarian cancer. J Cancer Res Clin Oncol. 2016;142:1509-20.
Adam R, Chiche L, Aloia T, Elias D, Salmon R, Rivoire M, et al. Hepatic resection for noncolorectal nonendocrine liver metastases: analysis of 1,452 patients and development of a prognostic model. Ann Surg. 2006;244:524-35.
Takada T, Yasuda H, Amano H, Yoshida M, Uchida T. Simultaneous hepatic resection with pancreato-duodenectomy for metastatic pancreatic head carcinoma: does it improve survival? Hepatogastroenterology. 1997;44:567-73.
Gleisner AL, Assumpcao L, Cameron JL, Wolfgang CL, Choti MA, Herman JM, et al. Is resection of periampullary or pancreatic adenocarcinoma with synchronous hepatic metastasis justified? Cancer. 2007;110:2484-92.
Shrikhande SV, Kleeff J, Reiser C, Weitz J, Hinz U, Esposito I, et al. Pancreatic resection for M1 pancreatic ductal adenocarcinoma. Ann Surg Oncol. 2007;14:118-27.
Seelig SK, Burkert B, Chromik AM, Tannapfel A, Uhl W, Seelig MH. Pancreatic resections for advanced M1-pancreatic carcinoma: the value of synchronous metastasectomy. HPB Surg. 2010;2010:579-672.
Klein F, Puhl G, Guckelberger O, Pelzer U, Pullankavumkal JR, Guel S, et al. The impact of simultaneous liver resection for occult liver metastases of pancreatic adenocarcinoma. Gastroenterol Res Pract. 2012;2012:939350.
Tachezy M, Gebauer F, Janot M, Uhl W, Zerbi A, Montorsi M, et al. Synchronous resections of hepatic oligometastatic pancreatic cancer: Disputing a principle in a time of safe pancreatic operations in a retrospective multicenter analysis. Surgery. 2016;160:136-44.
Andreou A, Knitter S, Klein F, Malinka T, Schmelzle M, Struecker B, et al. The role of hepatectomy for synchronous liver metastases from pancreatic adenocarcinoma. Surg Oncol. 2018;27:688-94.
de Jong MC, Tsai S, Cameron JL, Wolfgang CL, Hirose K, van Vledder MG, et al. Safety and efficacy of curative intent surgery for peri-ampullary liver metastasis. J Surg Oncol. 2010;102:256-63.
Schiergens TS, Luning J, Renz BW, Thomas M, Pratschke S, Feng H, et al. Liver resection for non-colorectal non-neuroendocrine metastases: Where do we stand today compared to colorectal cancer? J Gastrointest Surg. 2016;20:1163-72.
Hackert T, Niesen W, Hinz U, Tjaden C, Strobel O, Ulrich A, et al. Radical surgery of oligometastatic pancreatic cancer. Eur J Surg Oncol. 2017;43:358-63.
Crippa S, Bittoni A, Sebastiani E, Partelli S, Zanon S, Lanese A, et al. Is there a role for surgical resection in patients with pancreatic cancer with liver metastases responding to chemotherapy? Eur J Surg Oncol. 2016;42:1533-9.
Frigerio I, Regi P, Giardino A, Scopelliti F, Girelli R, Bassi C, et al. Downstaging in sage IV pancreatic cancer: A new population eligible for surgery? Ann Surg Oncol. 2017;24:2397-403.
Ruiz A, van Hillegersberg R, Siesling S, Castro-Benitez C, Sebagh M, Wicherts DA, et al. Surgical resection versus systemic therapy for breast cancer liver metastases: Results of a European case matched comparison. Eur J Cancer. 2018;95:1-10.
Abbas H, Erridge S, Sodergren MH, Papoulas M, Nawaz A, Menon K, et al. Breast cancer liver metastases in a UK tertiary centre: Outcomes following referral to tumour board meeting. Int J Surg. 2017;44:152-9.
Mariani P, Servois V, De Rycke Y, Bennett SP, Feron JG, Almubarak MM, et al. Liver metastases from breast cancer: Surgical resection or not? A case-matched control study in highly selected patients. Eur J Surg Oncol. 2013;39:1377-83.
Sadot E, Lee SY, Sofocleous CT, Solomon SB, Gönen M, Kingham TP, et al. Hepatic resection or ablation for isolated breast cancer liver metastasis: A case-control study with comparison to medically treated patients. Ann Surg. 2016;264:147-54.
Margonis GA, Buettner S, Sasaki K, Kim Y, Ratti F, Russolillo N, et al. The role of liver-directed surgery in patients with hepatic metastasis from primary breast cancer: a multi-institutional analysis. HPB (Oxford). 2016;18:700-5.
Ehrl D, Rothaug K, Hempel D, Rau HG. Importance of liver resection in case of hepatic breast cancer metastases. Hepatogastroenterology. 2013;60:2026-33.
Adam R, Aloia T, Krissat J, Bralet MP, Paule B, Giacchetti S, et al. Is liver resection justified for patients with hepatic metastases from breast cancer? Ann Surg. 2006;244:897-907.
Thelen A, Benckert C, Jonas S, Lopez-Hänninen E, Sehouli J, Neumann U, et al. Liver resection for metastases from breast cancer. J Surg Oncol. 2008;97:25-9.
Abbott DE, Brouquet A, Mittendorf EA, Andreou A, Meric-Bernstam F, Valero V, et al. Resection of liver metastases from breast cancer: estrogen receptor status and response to chemotherapy before metastasectomy define outcome. Surgery. 2012;151:710-6.
Bacalbasa N, Dima SO, Purtan-Purnichescu R, Herlea V, Popescu I. Role of surgical treatment in breast cancer liver metastases: a single center experience. Anticancer Res. 2014;34:5563-8.
Musunuru S, Chen H, Rajpal S, Stephani N, McDermott JC, Holen K, et al. Metastatic neuroendocrine hepatic tumors: resection improves survival. Arch Surg. 2006;141:1000-4.
Chen H, Hardacre JM, Uzar A, Cameron JL, Choti MA. Isolated liver metastases from neuroendocrine tumors: does resection prolong survival? J Am Coll Surg. 1998;187:88-92.
Touzios JG, Kiely JM, Pitt SC, Rilling WS, Quebbeman EJ, Wilson SD, et al. Neuroendocrine hepatic metastases: does aggressive management improve survival? Ann Surg. 2005;241:776-83.
Chamberlain RS, Canes D, Brown KT, Saltz L, Jarnagin W, Fong Y, et al. Hepatic neuroendocrine metastases: does intervention alter outcomes? J Am Coll Surg. 2000;190:432-45.
Osborne DA, Zervos EE, Strosberg J, Boe BA, Malafa M, Rosemurgy AS, et al. Improved outcome with cytoreduction versus embolization for symptomatic hepatic metastases of carcinoid and neuroendocrine tumors. Ann Surg Oncol. 2006;13:572-81.
Mayo SC, de Jong MC, Bloomston M, Pulitano C, Clary BM, Reddy SK, et al. Surgery versus intra-arterial therapy for neuroendocrine liver metastasis: a multicenter international analysis. Ann Surg Oncol. 2011;18:3657-65.
Yao KA, Talamonti MS, Nemcek A, Angelos P, Chrisman H, Skarda J, et al. Indications and results of liver resection and hepatic chemoembolization for metastatic gastrointestinal neuroendocrine tumors. Surgery. 2001;130:677-82.
Fairweather M, Swanson R, Wang J, Brais LK, Dutton T, Kulke MH, et al. Management of neuroendocrine tumor liver metastases: Long-term outcomes and prognostic factors from a large prospective database. Ann Surg Oncol. 2017;24:2319-25.
Partelli S, Inama M, Rinke A, Begum N, Valente R, Fendrich V, et al. Long-term outcomes of surgical management of pancreatic neuroendocrine tumors with synchronous liver metastases. Neuroendocrinology. 2015;102:68-76.
Landry CS, Scoggins CR, McMasters KM, Martin RC 2nd. Management of hepatic metastasis of gastrointestinal carcinoid tumors. J Surg Oncol. 2008;97:253-8.
Grazi GL, Cescon M, Pierangeli F, Ercolani G, Gardini A, Cavallari A, et al. Highly aggressive policy of hepatic resections for neuroendocrine liver metastases. Hepatogastroenterology. 2000;47:481-6.
Morgan RE, Pommier SJ, Pommier RF. Expanded criteria for debulking of liver metastasis also apply to pancreatic neuroendocrine tumors. Surgery. 2018;163:218-25.
Kobayashi S, Beppu T, Honda G, Yamamoto M, Takahashi K, Endo I, et al. Survival benefit of and indications for adjuvant chemotherapy for resected colorectal liver metastases-a Japanese Nationwide Survey. J Gastrointest Surg. 2020;24:1244-60.
Hatano E, Okuno M, Nakamura K, Ishii T, Seo S, Taura K, et al. Conversion to complete resection with mFOLFOX6 with bevacizumab or cetuximab based on K-ras status for unresectable colorectal liver metastasis (BECK study). J Hepatobiliary Pancreat Sci. 2015;22:634-45.
Morohashi H, Yokoyama H, Akasaka H, Sakamoto Y, Koyama M, Murata A, et al. Conversion therapy for synchronous colorectal liver metastases. Gan To Kagaku Ryoho. 2013;40:1665-7.
Kaibori M, Iwamoto S, Ishizaki M, Matsui K, Saito T, Yoshioka K, et al. Hepatic resection after neoadjuvant therapy for initially unresectable colorectal liver metastases. Gan To Kagaku Ryoho. 2009;36:2579-82.
Ychou M, Rivoire M, Thezenas S, Quenet F, Delpero JR, Rebischung C, et al. A randomized phase II trial of three intensified chemotherapy regimens in first-line treatment of colorectal cancer patients with initially unresectable or not optimally resectable liver metastases. The METHEP trial. Ann Surg Oncol. 2013;20:4289-97.
Wanis KN, Ardiles V, Alvarez FA, Tun-Abraham ME, Linehan D, de Santibañes E, et al. Intermediate-term survival and quality of life outcomes in patients with advanced colorectal liver metastases undergoing associating liver partition and portal vein ligation for staged hepatectomy. Surgery. 2018;163:691-7.
Koch C, Schmidt N, Winkelmann R, Eichler K, Pession U, Bechstein WO, et al. Anti-EGF receptor-based conversion chemotherapy in RAS wild-type colorectal cancer patients: Impact on survival and resection rates. Digestion. 2018;98:263-9.
Kawamura J, Yazawa T, Sumida K, Kida Y, Ogawa R, Tani M, et al. Clinical efficacy of liver resection after downsizing systemic chemotherapy for initially unresectable liver metastases. World J Surg Oncol. 2016;14:56.
Beppu T, Miyamoto Y, Sakamoto Y, Imai K, Nitta H, Hayashi H, et al. Chemotherapy and targeted therapy for patients with initially unresectable colorectal liver metastases, focusing on conversion hepatectomy and long-term survival. Ann Surg Oncol. 2014;21(Suppl 3):S405-413.
Galizia G, De Vita F, Lieto E, Zamboli A, Morgillo F, Castellano P, et al. Conversion chemotherapy followed by hepatic resection in colorectal cancer with initially unresectable liver-limited metastases. Oncol Rep. 2013;30:2992-8.
Devaud N, Kanji ZS, Dhani N, Grant RC, Shoushtari H, Serrano PE, et al. Liver resection after chemotherapy and tumour downsizing in patients with initially unresectable colorectal cancer liver metastases. HPB (Oxford). 2014;16:475-80.
Beppu T, Hayashi N, Masuda T, Komori H, Horino K, Hayashi H, et al. FOLFOX enables high resectability and excellent prognosis for initially unresectable colorectal liver metastases. Anticancer Res. 2010;30:1015-20.
Masi G, Loupakis F, Pollina L, Vasile E, Cupini S, Sergio Ricci S, et al. Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases. Ann Surg. 2009;249:420-5.
Andreou A, Viganò L, Zimmitti G, Seehofer D, Dreyer M, Pascher A, et al. Response to preoperative chemotherapy predicts survival in patients undergoing hepatectomy for liver metastases from gastric and esophageal cancer. J Gastrointest Surg. 2014;18:1974-86.
Takayanagi R, Takano S, Sugiura K, Yoshitomi H, Furukawa K, Takayashiki T, et al. Successful radical surgical resection of initially unresectable intrahepatic cholangiocarcinoma by downsizing chemotherapy with gemcitabine plus cisplatin: a case report. Surg Case Rep. 2017;3:116.